Effect of concurrent chemoradiotherapy with cisplatin and paclitaxel on immunological function and serum CYFRA21-1 and SCC-Ag in patients with middle and advanced cervical cancer

Objective: To explore the effect of concurrent chemoradiotherapy with cisplatin and paclitaxel on the immunological function and serum CYFRA21-1 and SCC-Ag in patients with middle and advanced cervical cancer. Methods: A total of 80 patients with middle and advanced cervical cancer who were admitted in our hospital from January, 2014 to January, 2016 were included in the study and randomized into the observation group and the control group with 40 cases in each group. The patients in the control group were given three-dimensional conformal radiotherapy of whole pelvic fields cassette, in a routine segmentation way, 2 GY/time, 5 time/week, DT50 GY/25F. On this basis, the patients in the observation group were given concurrent chemoradiotherapy with cisplatin and paclitaxel. The fasting venous blood before and after chemotherapy in the two groups was collected. FCM was used to detect the peripheral blood T lymphocyte subsets levels (CD3+ , CD4+ , and CD8+ ), and CD4+ /CD8+ was calculated. ECLIA was used to detect the serum CYFRA21-1 and SCC-Ag levels. Results: CD3+ , CD4+ , and CD4+ /CD8+ after treatment in the observation group were significantly elevated, and the reduced degree of CD8+ was significantly greater than that in the control group (P<0.05). The reduced degree of serum CYFRA21-1 and SCC-Ag after treatment in the observation group was significantly greater than that in the control group (P